The Paper's reporter Li Xiaoxiao
The fourth China International Import Expo (hereinafter referred to as the "Ciie") is about to open, and this year's medical equipment and medical care exhibition area still attracts the world's well-known multinational pharmaceutical companies.
Compared with the list of the top 20 pharmaceutical companies in the global revenue in 2020 compiled by the well-known pharmaceutical website fierce pharma, the surging news reporter found that more than half of the multinational pharmaceutical companies will participate in the Expo, including Johnson & Johnson, Roche, Novartis, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Sanofi, Takeda, AstraZeneca, Bayer, Eli Lilly, Boehringer Ingelheim and so on.
Judging from the highlights of the spoilers of the current participating pharmaceutical companies, the pharmaceutical companies that have participated in many sessions of the Expo, in addition to displaying innovative drugs in their own product lines, have also begun to establish more cooperative relations with local pharmaceutical forces through the Expo platform to promote the construction of China's local medical and health ecosystem.
A number of global innovative drugs collectively appeared at the Expo
Roche, headquartered in Switzerland, is participating in the Expo for the fourth time this year, and will bring more than ten new drugs and new indications, covering broad-spectrum anti-tumor, hematological tumors, rare diseases, breast tumors, gynecological tumors, immune tumors and influenza and other disease areas. Among them, the world's first broad-spectrum anti-tumor drug against ntrk (neurotrophic tyrosine receptor kinase) and ros1 (gene rearrangement) has been included in the "Guangdong-Hong Kong-Macao Greater Bay Area Drug Import Drug Catalogue" this year.
Pfizer is a multinational pharmaceutical company that has been in China for more than 30 years and has introduced more than 60 innovative drugs to China, including original drugs and vaccines. By 2025, Pfizer plans to introduce 24 new products, new indications, and new dosage forms to China. At this year's Expo, Pfizer will showcase its Asian debut in the five major areas of tumor, vaccine, anti-infection, inflammation and immunity, and rare diseases, and breakthrough innovative products and achievements in China's premiere, including loratinib, suglimab, 20-valent pneumococcal polysaccharide conjugate vaccine (pcv20), isaconazole sulfate cressemba (isavuconazole), cibinqo (abrocitinib), tofacitibu citrate extended-release tablets, etc.
Also on the contract of going to the Expo for four consecutive years is Bayer, which has signed the fifth session in advance. For the innovative drugs exhibited at the Expo, Zhou Xiaolan, global executive vice president of Bayer Group's prescription drugs division, president of China, and president of Bayer Group Greater China, previously revealed to the surging news reporter that nobegro, a new drug for the treatment of prostate cancer, will be unveiled, which is an oral androgen receptor inhibitor for the treatment of non-metastatic castration-resistant prostate cancer with high risk of metastasis, which has been listed in China this year.
Another multinational pharmaceutical company, GSK, is participating in the Expo for the third year, and this year's Expo will bring a number of blockbuster products, including the first complete, once-daily, single-dose AIDS dual-drug treatment program doveto (Lamivudine dotiravir tablets) in China this year, Pyridon (Belijuzub), which is used to treat systemic lupus erythematosus, and the world's first approved marketed target human interleukin biological preparation new Kolai (mepolilizumab).
Before the Expo, Qi Xin, vice president of GSK and general manager of China's prescription drugs and vaccines, said in an interview with the surging news reporter that GSK's product line is particularly wide, with mature product lines and innovative product lines, and when choosing which product to introduce, it often looks at the local disease spectrum to ensure that innovative products can truly meet the unmet health needs of the Chinese market.
In fact, focusing on the unmet needs of Chinese health is the logic of many multinational pharmaceutical companies introducing innovative drugs in China. It is foreseeable that with the help of the spillover effect of the Expo, more and more exhibits will become commodities, and as more and more innovative drugs are approved and landed, more Chinese patients will benefit.
Multinational pharmaceutical companies promote local cooperation through the Expo
With the development of the pharmaceutical industry, multinational pharmaceutical companies are no longer just pharmaceutical manufacturers, how to accelerate the accessibility of innovative drugs, how to create an ecosystem with other partners in the pharmaceutical industry, etc. have become the direction of more and more multinational pharmaceutical companies. It can be seen that many of the actions in this regard have been announced through the platform of the Expo.
Taking AstraZeneca as an example, this year's CIIE will showcase its smart medical integrated health management services, including smart pharmacies, e-commerce platforms, Internet hospitals, etc., mainly demonstrating that AstraZeneca and partners in the retail and Internet fields jointly improve the accessibility of high-quality drugs and medical service capabilities.
In terms of Internet hospitals, AstraZeneca and third-party Internet hospitals are carrying out extensive cooperation, among them, Huiyi Tianxia Internet Medical Platform as one of the display partners, the Expo will present "Internet +" to empower the whole course of chronic disease management, for patients to create an online and offline integrated medical service chain closed loop including early screening, online consultation, follow-up management and live broadcast of patients.
During this year's Expo, Roche will also join hands with partners from all sides such as industry, politics, academia and research to bring a number of innovative achievements. It is worth mentioning that its Roche China Accelerator, which has invested nearly 300 million yuan, will usher in the "debut of Bo", which is the first accelerator independently established and operated by Roche in the world, aiming to find excellent local biotechnology and pharmaceutical companies and help promote the accelerated development of medical innovation in China through cooperation with domestic enterprises in research and development.
In addition, Roche also revealed that at this year's booth, Roche will reach a strategic alliance with a number of local innovative enterprises, work together to create an online and offline integration system, and jointly promote the construction of the "early detection, early diagnosis, early treatment" ecosystem of cancer prevention and treatment.
For the importance of cooperation with Local Chinese enterprises, Peng Zhenke, President of Pfizer Biopharmaceutical Group China, said in an interview with the surging news reporter on the eve of the Expo that multinational pharmaceutical companies want to achieve innovation strategies in China, in addition to relying on innovative businesses and innovative products, a very important pillar is partnership. Pfizer will further accelerate innovative collaborations with homegrown biopharmaceutical and biotech companies, which will bring great benefits to both parties.
Editor-in-Charge: It's Winter
Proofreader: Luan Meng